The company announced the acquisition of Oncology Information Service e.K. and its subsidiary Cancer Data Net.
riNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, today announced the acquisition of OncologyInformationService e.K. (OIS) and its subsidiary Cancer Data Net GmbH (CDN), a German-based company and the subsidiary a Swiss-based company. Both companies provide real-world data (RWD) driven solutions across Europe.
Their capabilities include longitudinal collection of retrospective data obtained from medical charts, consultative and operational services in epidemiology, HTA, HEOR, such as definition of target population (treated prevalence and incidence), standard of care, and building synthetic arms for RCTs. The multi-level data management provides regulatory-grade quality of data sets. Prior to the acquisition, OIS was certified as an OMOP SME in the EHDEN framework. Its team of data analysts opens a new era in statistical analysis of RWD using machine learning models and predictive statistics.
“OIS/CDN is a strategic acquisition that adds deep, regulatory-grade transferable oncology data from Europe and greatly enhances our global footprint of the TriNetX network,” said Gadi Lachman, CEO of TriNetX. “It also expands TriNetX’s ability to deliver projects and data for use by FDA and European Medicines Agency in order to support regulatory decision-making in the oncology space.”
OIS/CDN conducts each project based on a regionally representative sample in the respective target population and has gathered regulatory-grade longitudinal data for more than 15 cancer types for a multitude of use cases. Both companies currently collaborate with the largest manufacturers of anti-cancer therapeutics, emerging other innovative companies, and research networks.